Compare OLPX & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLPX | TBPH |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 824.9M |
| IPO Year | 2021 | 2013 |
| Metric | OLPX | TBPH |
|---|---|---|
| Price | $2.03 | $16.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $1.89 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 6.7M | 474.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | ★ $422,960,000.00 | $15,386,000.00 |
| Revenue This Year | $2.95 | $1.04 |
| Revenue Next Year | $3.39 | N/A |
| P/E Ratio | ★ N/A | $8.06 |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $0.99 | $8.33 |
| 52 Week High | $2.04 | $21.03 |
| Indicator | OLPX | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 72.30 | 57.29 |
| Support Level | $1.20 | $13.41 |
| Resistance Level | $2.04 | $19.04 |
| Average True Range (ATR) | 0.01 | 0.52 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 70.00 | 78.60 |
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.